There are so many useful reports in health care that aid in understanding what kind of care is being utilized and what the costs are. In regard to pharmaceuticals, the regular IMS report on Global Use of Medicines is one of the best. (IMS Report) The headline catching number is that worldwide drug spending was projected to be over one trillion dollars in 2014, rising to $1.2 trillion in 2017. That is a huge industry by any standard. The global market is showing an interesting divergence, with most developed countries having only single-digit drug spending growth, while some newly developed and emerging economies provide opportunities for more rapid growth as they spend more on health care, both privately and publicly. For drug companies this has meant increased attention to these newer markets, which can be challenging from a regulatory and reimbursement perspective, but which may provide better returns than existing developed markets. In regard to the development of new therapeutics, innovation now and for the next few years is focused on specialty drugs which either treat less common diseases or new biologic approaches to somewhat common diseases that do not currently have treatments with high levels of clinician or patient satisfaction. The top therapeutic classes in developed markets in 2017 are projected to be oncology, diabetes, arthritis, and pain; and in emerging markets to be pain, CNS agents, antibiotics and oncology. As we are seeing in the United States, it is apparent that much of cost of drugs will be driven by expensive new biologic agents, which are harder to develop and manufacture and which tend to retain higher costs for a longer period of time due to difficulty of “genericizing” these drugs.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
What do you get when you combine a company with a commodity business model, that out of desperation massively overpays for another company that has a commodity business model? $10...
July 27, 2022
The “stupid” model for health care venture capital investing is alive and well. Everside health, which operates primary care clinics and has grown by acquiring other failing health care businesses,...
July 26, 2022
Apparently not even a cute name can save you if you have a stupid business. I constantly bemoan the mis-application of capital and health care is Exhibit A. Olive, another...
July 26, 2022
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace